Compare ACHR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHR | GKOS |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Aerospace | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.3B |
| IPO Year | N/A | N/A |
| Metric | ACHR | GKOS |
|---|---|---|
| Price | $6.78 | $107.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $12.14 | ★ $132.00 |
| AVG Volume (30 Days) | ★ 36.2M | 818.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $33.04 |
| Revenue Next Year | N/A | $22.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.48 | $73.16 |
| 52 Week High | $14.62 | $161.78 |
| Indicator | ACHR | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 40.71 |
| Support Level | $6.61 | $105.37 |
| Resistance Level | $7.57 | $115.19 |
| Average True Range (ATR) | 0.40 | 4.91 |
| MACD | -0.05 | -1.48 |
| Stochastic Oscillator | 22.45 | 11.57 |
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.